Skip to main content

A nanovaccine Approach for the treatment of Pancreatic Cancer

Objective

A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success.
Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bile duct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project
is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.

Call for proposal

H2020-MSCA-ITN-2019
See other projects for this call

Coordinator

PERCUROS BV
Address
Eerbeeklaan 42
2573 HT 'S-gravenhage
Netherlands
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 265 619,88

Participants (14)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 531 239,76
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITEIT DELFT
Netherlands
EU contribution
€ 265 619,88
Address
Stevinweg 1
2628 CN Delft
Activity type
Higher or Secondary Education Establishments
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 505 576,80
Address
Hofgartenstrasse 8
80539 Munchen
Activity type
Research Organisations
THE UNIVERSITY OF BIRMINGHAM
United Kingdom
EU contribution
€ 303 172,56
Address
Edgbaston
B15 2TT Birmingham
Activity type
Higher or Secondary Education Establishments
GOOD BIOMARKER SCIENCES BV
Netherlands
EU contribution
€ 265 619,88
Address
Teijlingerlaan 59
2171 CD Sassenheim
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 265 619,88
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 252 788,40
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
KLINIKUM DER UNIVERSITAET REGENSBURG

Participation ended

Germany
EU contribution
€ 0
Address
Frans Josef Strauss Allee 11
93053 Regensburg
Activity type
Higher or Secondary Education Establishments
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 274 802,04
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
UNIVERSITAT DE BARCELONA
Spain
EU contribution
€ 250 904,88
Address
Gran Via De Les Corts Catalanes 585
08007 Barcelona
Activity type
Higher or Secondary Education Establishments
DANMARKS TEKNISKE UNIVERSITET

Participation ended

Denmark
EU contribution
€ 0
Address
Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby
Activity type
Higher or Secondary Education Establishments
POLYPURE AS
Norway
EU contribution
€ 292 342,32
Address
Gaustadalleen 21
0349 Oslo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
STATENS SERUM INSTITUT
Denmark
EU contribution
€ 297 522
Address
Artillerivej 5
2300 Kobenhavn S
Activity type
Research Organisations
STIFTUNG REGENSBURGER CENTRUM FUR INTERVENTIONELLE IMMUNOLOGIE
Germany
EU contribution
€ 252 788,40
Address
Franz Josef Strauss Allee 11
93053 Regensburg
Activity type
Research Organisations